In a written reply to Rajya Sabha, Minister of State for Chemicals and Fertilisers, Anupriya Patel said that as of March 2025, against an investment commitment of Rs 3,938.5 crore over the period of six years, investment of Rs 4,570 crore has already been made under the PLI Scheme for Bulk Drugs.
Drugs (Source: unsplash)
Imports of pharma raw materials worth Rs 1,362 crore have been avoided till March 2025 due to the creation of domestic manufacturing capacity for 25 identified items under the production-linked incentive scheme for bulk drugs, Parliament was informed on Tuesday.
In a written reply to Rajya Sabha, Minister of State for Chemicals and Fertilisers, Anupriya Patel said that as of March 2025, against an investment commitment of Rs 3,938.5 crore over the period of six years, investment of Rs 4,570 crore has already been made under the PLI Scheme for Bulk Drugs.
"As a result of the scheme, cumulative sales of Rs 1,817 crore have been reported over the period from the beginning of the scheme till March 2025, including exports of Rs 455 crore, thereby avoiding imports worth Rs 1,362 crore and creation of domestic manufacturing capacity for 25 identified KSMs/DIs/APIs," she stated.
By continuing you agree to our Privacy Policy & Terms & Conditions
